EN
/
SE

Press Releases

  • All
  • Staff change
  • Regulatory
  • PR
  • Other Corporate Information
  • Other
  • News
  • mfn-cus-disclaimer
  • Listing Regulation
  • IR
  • Executive staff changes
  • English
  • Corporate Information
  • Corporate Action
  • 2024
  • 2023
  • 2022
  • 2021

Occlutech® Announces Commercial Cases of Occlutech ASD Occluder Device Implantation in the U.S.

August 28, 2024
Read More

Occlutech Q2 Update: Strong Growth, Efficiency, and Strategic Execution

August 15, 2024
Read More

Occlutech Q1 2024 – Performance Update: A Strong Start to the Year

May 28, 2024
Read More

Occlutech Q4 2023 – key approval in the US, solid progress in clinical study and continued strong growth

March 5, 2024
Read More

Occlutech® Announces FDA Approval of its Occlutech® ASD Occluder and Occlutech® Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects

January 8, 2024
Read More

Occlutech Q3 2023 – Achieving continued growth across geographies and sales channels with a positive outlook for year end

December 6, 2023
Read More

Occlutech Q2 2023 – Continued strong revenue growth

September 5, 2023
Read More

Occlutech Q1 2023 – Growth momentum with increased sales and marketing activities

May 26, 2023
Read More

Occlutech Year-end report 2022 – Significant uptick in sales growth as transformation processes are reaching an end

May 3, 2023
Read More

Occlutech receives subscription commitment of bonds amounting to EUR 40 million in nominal value under a total frame of EUR 75 million to finance US expansion and growth

April 5, 2023
Read More
Load More Press Releases
Subscribe

Please select a site

International
The United States